[{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Telazorlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ichnos Sciences \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ichnos Sciences \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Torqur","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"Pan-PI3K\/mTOR","graph1":"Dermatology","graph2":"Phase II","graph3":"Torqur","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Torqur \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Torqur \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Helix BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake Immunotherapeutics \/ Helix BioPharma"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake Immunotherapeutics \/ Merck & Co"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Bimiralisib is a selective pan-PI3K/mTOR inhibitor, which is being evaluated for the topical treatment of actinic keratosis of the face or scalp.

                          Product Name : PQR309

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 07, 2025

                          Lead Product(s) : Bimiralisib

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : M1095 (sonelokimab) is a humanized Nanobody® being evaluated for hidradenitis suppurativa treatment, consisting of three VHH domains linked by flexible spacers.

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 26, 2024

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : M1095 (sonelokimab) is a humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with IL-17A and IL-17F and inhibit IL-17A/A, IL-17A/F, and IL-17F/F dimer, which investigated for moder...

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          October 15, 2023

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : MoonLake intends to use the net proceeds to fund the ongoing advancement of M1095 (sonelokimab), a trivalent monomeric nanobody that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F for the treatment of inflammatory diseases.

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          June 28, 2023

                          Lead Product(s) : Sonelokimab,Adalimumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : SVB Securities

                          Deal Size : $400.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : M1095 (sonelokimab) is a humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with IL-17A and IL-17F and inhibit IL-17A/A, IL-17A/F, and IL-17F/F dimer, which investigated for hidra...

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 25, 2023

                          Lead Product(s) : Sonelokimab,Adalimumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : M1095 (sonelokimab) is a humanized nanobody® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with high affinity to IL-17A and IL-17F and inhibits IL-17A/A, IL-17A/F, and IL-17F/F dimers.

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 02, 2023

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : M1095 (sonelokimab) inhibits the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. In addition, sonelokimab is designed to directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues.

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          December 05, 2022

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Sonelokimab (M1095), is MoonLake’s investigational Nanobody® designed to treat inflammatory disease by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          July 26, 2022

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Vetter Pharma-Fertigung GmbH & Co

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : MoonLake plans to execute on its development program to unlock the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          May 04, 2022

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Helix BioPharma

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Proceeds from the transaction are expected to provide MoonLake with the capital needed to accelerate the development of the clinical stage, tri-specific Nanobody® sonelokimab, in multiple inflammatory diseases in dermatology and rheumatology driven by I...

                          Product Name : M1095

                          Product Type : Antibody

                          Upfront Cash : $230.0 million

                          April 10, 2021

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Helix BioPharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank